

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the approximate response rate with tucatinib/trastuzumab for patients with previously treated HER2-positive, RAS wild-type metastatic colorectal cancer (CRC) in the Phase II MOUNTAINEER trial?
 - a. 10%
 - b. 40%**
 - c. Higher than 70%
2. What was the approximate median duration of response to tucatinib/trastuzumab for patients with previously treated HER2-positive, RAS wild-type metastatic CRC in the Phase II MOUNTAINEER trial?
 - a. 3 months
 - b. 6 months
 - c. 12 months**
 - d. 24 months
3. Which of the following statements best describes the relationship between median progression-free survival (PFS) and Grade ≥ 2 chemotherapy-induced neutropenia (CIN) among patients with relapsed/refractory CRC receiving TAS-102 with bevacizumab in the Phase III SUNLIGHT study?
 - a. PFS was better for patients with CIN
 - b. PFS was better for patients without CIN**
 - c. CIN did not appear to correlate with treatment benefit
4. What is the target of the novel agent botensilimab under investigation for patients with heavily pretreated microsatellite-stable metastatic CRC?
 - a. BRAF V600E
 - b. CTLA-4**
 - c. NRAS
 - d. KRAS G12C
5. What was the pathologic complete response rate observed for patients with mismatch repair-deficient/microsatellite instability-high CRC receiving neoadjuvant nivolumab with ipilimumab followed by single-agent nivolumab in the Phase III NICHE-2 study?
 - a. Lower than 20%
 - b. 33%
 - c. 50%
 - d. Higher than 60%**